March 2, 2015
RESEARCH TRIANGLE PARK, N.C – Humacyte, a pioneer in biotechnology and regenerative medicine, announced today that the Company has been awarded the 2015 North Carolina Excellence Award by the US Commerce & Trade Research Institute (USCTRI), a leading research authority that evaluates and recognizes businesses and organizations that have made a significant contribution in enterprise and entrepreneurial growth.
Humacyte was recognized with the North Carolina Excellence Award for demonstrating strong business ethics and company values, and the Company’s high-level of business leadership throughout the biotechnology industry and the research community. The honor further recognizes Humacyte’s contribution as an emerging leader within the community, showcasing an unabashed innovative, and entrepreneurial spirit.
Humacyte is developing the first bioengineered, off-the-shelf, human tissue blood vessel. Humacyte’s human acellular vessel (HAV) has received ‘Fast Track’ designation from the Food and Drug Administration, expediting the regulatory review process, and potentially, speed to market.
“We are very pleased to be honored again with the prestigious North Carolina Excellence Award,” said Ted Lithgow, Ph.D., Humacyte’s chief operating officer. “We work among some of the “brightest and best” in Research Triangle Park, and we are humbled to be recognized among a prolific group of peers. This is an exciting time at Humacyte, as we continue the development of our human acellular vessel for patients with End Stage Renal Disease who require dialysis.”
Annually, the USCTRI conducts business surveys and industry research to identify companies that have achieved measurable success in their local business environment and industry category. The award recognizes those that have enhanced the commitment and contribution of small businesses through service to their customers and community. Small businesses of this caliber enhance the consumer driven stature that North Carolina is renowned for.
Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
The USCTRI is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized locally and encouraged globally. Particular emphasis is given to meeting and exceeding industry benchmarks for customer service, product quality and ethical practices. Industry leading standards and practices have been developed and implementation of the same has been pioneered by the dedicated efforts of the business community and commerce leadership.